Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells

2007 ◽  
Vol 213 (4) ◽  
pp. 402-411 ◽  
Author(s):  
M-H Wang ◽  
W Lee ◽  
Y-L Luo ◽  
MT Weis ◽  
H-P Yao
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Receptor Tyrosine Kinase ◽  
Altered Expression ◽  
Epithelial Cancers ◽  
Ron Receptor ◽  
Thyroid Cancer Cells

scholarly journals Smad4-dependent TGF-β Signaling Suppresses RON Receptor Tyrosine Kinase-dependent Motility and Invasion of Pancreatic Cancer Cells

2008 ◽  
Vol 283 (17) ◽  
pp. 11293-11301 ◽  
Author(s):  
Shujie Zhao ◽  
Sudhakar Ammanamanchi ◽  
Michael Brattain ◽  
Lin Cao ◽  
Amalraj Thangasamy ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Receptor Tyrosine Kinase ◽  
Pancreatic Cancer Cells ◽  
Ron Receptor

scholarly journals The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells

2011 ◽  
Vol 96 (6) ◽  
pp. E991-E995 ◽  
Author(s):  
Hans H. G. Verbeek ◽  
Maria M. Alves ◽  
Jan-Willem B. de Groot ◽  
Jan Osinga ◽  
John T. M. Plukker ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Tyrosine Kinase Inhibitors ◽  
Papillary Thyroid Cancer ◽  
Kinase Inhibitors ◽  
Papillary Thyroid ◽  
Thyroid Cancer Cells

Selective tyrosine kinase inhibitor, STI571, inhibits growth of p53 mutant anaplastic thyroid cancer cells by inducing S–G2 transition arrest

2003 ◽  
Vol 1258 ◽  
pp. 157-161
Author(s):  
Alexei P Podtcheko ◽  
Satoshi Tsuda ◽  
Akira Ohtsuru ◽  
Vladimir A Saenko ◽  
Junichi KurebayashiI ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Kinase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells

scholarly journals Altered Expression of c-IAP1, Survivin, and Smac Contributes to Chemotherapy Resistance in Thyroid Cancer Cells

2006 ◽  
Vol 66 (8) ◽  
pp. 4263-4272 ◽  
Author(s):  
Elena Tirrò ◽  
Maria Letizia Consoli ◽  
Michele Massimino ◽  
Livia Manzella ◽  
Francesco Frasca ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Chemotherapy Resistance ◽  
Altered Expression ◽  
Thyroid Cancer Cells

scholarly journals The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells

2003 ◽  
Vol 88 (4) ◽  
pp. 1889-1896 ◽  
Author(s):  
Alexei Podtcheko ◽  
Akira Ohtsuru ◽  
Satoshi Tsuda ◽  
Hirouki Namba ◽  
Vladimir Saenko ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Kinase Inhibitor ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Cancer Cells

scholarly journals Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 248 ◽  
Author(s):  
Ramya Lakshmi Rajendran ◽  
Sanjita Paudel ◽  
Prakash Gangadaran ◽  
Ji Min Oh ◽  
Eun Jung Oh ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Cancer Cells ◽  
Tyrosine Kinase Inhibitors ◽  
Extracellular Vesicles ◽  
Radioactive Iodine ◽  
Kinase Inhibitors ◽  
Stem Cell Markers ◽  
Thyroid Cancer Cells

A new approach for using extracellular vesicles (EVs) to deliver tyrosine kinase inhibitors (TKIs) to enhance iodine avidity in radioactive iodine-refractory thyroid cancer is needed. We isolated and characterized primary human adipose-derived stem cells (ADSCs) and isolated their EVs. The EVs were characterized by transmission electron microscopy, nanoparticle tracking analysis, and western blotting. A new TKI was loaded into the EVs by incubation (37 °C; 10 min) or sonication (18 cycles; 4 s per cycle) with 2 s intervals and a 2 min ice bath every six cycles. TKI loading was confirmed and measured by mass spectrometry. EV uptake into radioactive iodine-refractory thyroid cancer cells (SW1736 cells) was confirmed by microscopy. We treated the SW1736 cells with vehicle, TKI, or TKI-loaded EVs (sonication TKI-loaded EVs [EVsTKI(S)]) and examined the expression of iodide-metabolizing proteins and radioiodine uptake in the SW1736 cells. ADSCs cells showed >99% of typical stem cell markers, such as CD90 and CD105. The EVs displayed a round morphology, had an average size of 211.4 ± 3.83 nm, and were positive for CD81 and Alix and negative for cytochrome c. The mass spectrometry results indicate that the sonication method loaded ~4 times more of the TKI than did the incubation method. The EVsTKI(S) were used for further experiments. Higher expression levels of iodide-metabolizing mRNA and proteins in the EVsTKI(S)-treated SW1736 cells than in TKI-treated SW1736 cells were confirmed. EVsTKI(S) treatment enhanced 125I uptake in the recipient SW1736 cells compared with free-TKI treatment. This is the first study that demonstrated successful delivery of a TKI to radioactive iodine-refractory thyroid cancer cells using EVs as the delivery vehicle. This approach can revert radioiodine-resistant thyroid cancer cells back to radioiodine-sensitive thyroid cancer cells.

Sign in / Sign up

Export Citation Format

Share Document